|Day Low/High||31.88 / 34.21|
|52 Wk Low/High||11.57 / 116.75|
Many traders follow trends, but these can change quickly, sending a stock plummeting. There are signals that will help a trader know how to avoid this type of pattern.
Tesaro expects to file a new drug application before the end of the year for niraparib as a maintenance therapy for ovarian cancer.
Clovis Oncology (CLVS) gave an update on a clinical trial for its rucaparib drug on Friday, showing its candidate might be inferior to competitors.
Takeover speculation that had fueled the recent rise in Clovis' stock price looks to be subsiding.
Clovis Oncology (NASDAQ:CLVS) announced today the oral presentation of the primary efficacy and safety data from its NDA dataset for rucaparib at the 2016 ESMO Congress in Copenhagen.
A cancer research meeting beginning on Friday will provide investors with an opportunity to inspect updated clinical data on two competing PARP inhibitors from Clovis Oncology and Tesaro.
Deutsche Bank's problems have investors worried about another Lehman failure, Cramer says.
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that data from its rucaparib program in ovarian cancer will be presented at the annual European Society for Medical Oncology (ESMO) 2016 Congress.
Rumors are swirling about Big Pharma interest in the cancer drug developer, but the validity of such theories is questioned by at least some company followers.
Cramer is sticking with Weyerhaeuser and thinks Taser is a buy.
Some companies have powerful trends to bolster their numbers, Fed or no Fed, Cramer says.
Clovis Oncology shares were higher Wednesday after analysts with Credit Suisse boosted the stock's rating to OUTPERFORM from NEUTRAL.
The technical signs indicate the stock's price and volume are going up without a dip.
Clovis Oncology's (CLVS) stock rating was lifted to 'outperform' at Credit Suisse on takeover talk.
Wall Street eyes the Fed's decision on interest rates as Mylan's CEO goes to Capital Hill over the EpiPen.
Here are Wednesday's top research calls, including an upgrade for Clovis Oncology, downgrades for Sketchers USA and Wells Fargo and new coverage for Altria.
Gilead Sciences (GILD) said at the Wells Fargo Conference on Thursday that it is considering investing in a PARP inhibitor like Clovis Oncology's (CLVS) rucaparib.
Clovis Oncology (CLVS) agreed with Pfizer (PFE) to defer payments for its rucaparib ovarian cancer drug late Tuesday.
Cramer says CyberArk Software is doing well but he's avoiding Clovis Oncology.
Cramer says he doesn't understand the obsession some investors have with the Federal Reserve. Forget the Fed.
Here's a technical look at how to trade some of the most active stocks on the market right now.
In recent trading, shares of Clovis Oncology Inc have crossed above the average analyst 12-month target price of $21.17, changing hands for $23.03/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
The FDA granted accelerated approval for Clovis Oncology's (CLVS) rucaparib drug.
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended June 30, 2016, and provided an update on the Company's clinical development programs and regulatory outlook for the remainder of...
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2016 financial results on Monday, August 8, 2016, after the close of the U.
Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.
Clovis Oncology (NASDAQ:CLVS) announced updated phase 2 results from Part 1 of the ongoing ARIEL2 study in patients with advanced ovarian cancer as well as the final results of the RUCAPANC study of rucaparib in...